

Metric Name: MONITORING FOR NEPHROPATHY

Care Category: Diabetes Management

Definition: The percentage of members 18–64 years of age with Diabetes (type 1 or type 2) who had the following: Monitoring for Nephropathy.

Eligible Population Requirements

Please refer to the “BCBSF_PP2012_Abstract_Diabetes” document for details on the population identification.

Metric Determination

Denominator: Members meeting all eligible population requirements, less excluded members.

Numerator: A nephropathy screening test or evidence of nephropathy, as documented through administrative data. Refer to Table E under “Supporting Specifications” for a list of applicable codes to identify nephropathy screening tests. Refer to Table F under “Supporting Specifications” for a list of applicable codes to identify evidence of nephropathy. Refer to Table G under “Supporting Specifications” for a list of ACE inhibitors/ARBs.

Source(s): HEDIS 2012 Technical Specification Manual.²
HEDIS 2012 Technical Update (Oct 2011), if applicable.

Supporting Specifications

Table E: Codes to Identify Nephropathy Screening Tests

Description	CPT	CPT Category II	LOINC
Nephropathy screening test	82042, 82043, 82044, 84156	3060F, 3061F	1753-3, 1754-1, 1755-8, 1757-4, 2887-8, 2888-6, 2889-4, 2890-2, 9318-7, 11218-5, 12842-1, 13801-6, 14956-7, 14957-5, 14958-3, 14959-1, 13705-9, 14585-4, 18373-1, 20621-9, 21059-1, 21482-5, 26801-1, 27298-9, 30000-4, 30001-2, 30003-8, 32209-9, 32294-1, 32551-4, 34366-5, 35663-4, 40486-3, 40662-9, 40663-7, 43605-5, 43606-3, 43607-1, 44292-1, 47558-2, 49023-5, 50949-7, 53121-0, 53530-2, 53531-0, 53532-8, 56553-1, 57369-1, 58448-2, 58992-9, 59159-4

² Although this measure is usually performed on a hybrid basis whereby medical records are used to confirm and/or substantiate qualifying numerator events, sufficient medical experience can be found in administrative claims to warrant evaluation.

Evidence of nephropathy

Any of the following meet criteria for evidence of nephropathy.

A claim/encounter with a code to indicate evidence of nephropathy (Table F) during the measurement period.

A nephrologist visit during the measurement period, as identified by the MCO’s specialty-provider codes (no restriction on the diagnosis or procedure code submitted).

A positive urine microalbumin test in the measurement period, as documented by claim/encounter or automated laboratory data. Use the codes in Table F to identify urine microalbumin tests. For tests identified by LOINC codes use automated laboratory data to confirm a positive result. “Trace” urine microalbumin test results are not considered numerator-compliant.

Evidence of ACE inhibitor/ARB therapy during the measurement period. Members who had a claim indicating therapy (Table F), or who received an ambulatory prescription or were dispensed an ambulatory prescription for ACE inhibitors or ARBs during the measurement period are compliant. Table G lists the ACE inhibitors/ARBs included in this measure.

Table F: Codes to Identify Evidence of Nephropathy

Description	Urine micro-albumin test*	Evidence of treatment for nephropathy	ACE inhibitor/ARB therapy
CPT	81000-81003, 81005	36145, 36147, 36800, 36810, 36815, 36818, 36819-36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90935, 90937, 90940, 90945, 90947, 90957-90962, 90965, 90966, 90969, 90970, 90989, 90993, 90997, 90999, 99512	
CPT Cat II	3062F	3066F	4009F
HCPCS		G0257, G0392, G0393, S9339	
ICD-9 Diagnosis		250.4, 403, 404, 405.01, 405.11, 405.91, 580-588, 753.0, 753.1, 791.0, V42.0, V45.1	
ICD-9 Procedure		38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.4-55.6	
UB04 Revenue		0367, 080x, 082x-085x, 088x	
Type of Bill		72x	
POS		65	
LOINC	5804-0, 20454-5, 50561-0, 53525-2, 57735-3		

* A CPT Category II code indicates a positive result for urine microalbumin; automated laboratory data must be used to confirm a positive result for tests identified by CPT or LOINC codes.

Table G: ACE Inhibitors/ARBs³

Description	Prescription				
Angiotensin converting enzyme inhibitors	Benazepril Captopril	Enalapril Fosinopril	Lisinopril Moexipril	Perindopril Quinapril	Ramipril Trandolapril
Angiotensin II inhibitors	Azilsartan Candesartan	Eprosartan Irbesartan	Losartan Olmesartan	Telmisartan Valsartan	
Antihypertensive combinations	Aliskiren-valsartan Aliskiren-hydrochlorothiazide-amlodipine Amlodipine-benazepril Amlodipine-hydrochlorothiazide-valsartan Amlodipine-hydrochlorothiazide-olmesartan Amlodipine-olmesartan Amlodipine-telmisartan Amlodipine-valsartan			Benazepril-hydrochlorothiazide Candesartan-hydrochlorothiazide Captopril-hydrochlorothiazide Enalapril-hydrochlorothiazide Eprosartan-hydrochlorothiazide Fosinopril-hydrochlorothiazide Hydrochlorothiazide-irbesartan Hydrochlorothiazide-lisinopril	Hydrochlorothiazide-losartan Hydrochlorothiazide-moexipril Hydrochlorothiazide-olmesartan Hydrochlorothiazide-quinapril Hydrochlorothiazide-telmisartan Hydrochlorothiazide-valsartan Trandolapril-verapamil

³ NCQA provides a comprehensive list of NDC codes on its Web site (www.ncqa.org) for each reporting cycle.
Quality Metrics